Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late entry biopharma strategy is therefore essential for any leadership team evaluating follower assets.
Over the past decade, roughly half of all innovative branded launches have entered as second or later products within an established class. Some have gone on to reshape standards of care and generate blockbuster sales. Many others have failed to gain traction. The pattern is clear: late entry can work, but only under very specific conditions.
Three factors consistently separate winners from underperformers: how quickly a product enters the market after the first to market, how meaningfully it improves on existing therapies, and whether the sponsoring company has the capabilities to execute at scale.
The two-year window that defines success
Timing is the first, and often most underestimated, driver of commercial performance.
In the early period following the launch of a new therapeutic class, the market remains fluid. Physicians are still forming prescribing habits, clinical guidelines are evolving, and payers are determining how to position and reimburse new therapies. This uncertainty creates a critical opportunity for “fast followers.”
Products launched within roughly two years of the first-in-class entrant consistently outperform later arrivals, achieving close to three times higher average sales by year five. This timing dynamic sits at the heart of any credible late entry biopharma strategy. Entering during this window allows companies to participate in shaping treatment paradigms rather than compete against them.
Beyond that point, the dynamics change fundamentally. As prescribing behaviour becomes more entrenched, physicians place greater confidence in established treatments, and formularies and reimbursement pathways become more fixed. As a result, the clinical, operational, and financial costs of switching increase.
For companies entering later, the bar rises sharply. Competing effectively is no longer about participation in the class. It becomes a question of displacement.
Clinical differentiation is not optional – it is decisive
Timing can give a company an advantage, but ultimately, success depends on how clearly it can differentiate itself from the competition.
Late entrants that succeed almost always deliver clinically meaningful advantages over existing therapies. Incremental improvements are rarely enough. The market rewards products that shift clinical expectations, particularly through superior efficacy or improved safety profiles.
Among late entrants that outperform expectations, a significant proportion do so on the back of superior efficacy, often demonstrated through head-to-head trials. These therapies redefine treatment benchmarks, prompting physicians to reconsider established prescribing habits.
Safety can also be a powerful lever, especially in chronic conditions. Products that materially reduce serious adverse events or eliminate key safety concerns associated with earlier therapies can shift the risk-benefit equation in ways that drive adoption, even in well-established markets.
By contrast, convenience alone is seldom sufficient. Improvements such as less frequent dosing or alternative formulations can support uptake, but they rarely drive it on their own. Without clear clinical superiority, convenience-led strategies tend to deliver modest gains at best.
This means late entrants must justify their existence with meaningful benefits to patients. Statistical improvements are not enough. The advantage must be clinically relevant, visible in practice, and compelling enough to change behaviour.
Scale separates contenders from winners
Even with strong differentiation, execution matters, and this is where company scale becomes a decisive factor.
Large biopharma companies bring structural advantages that are difficult to replicate. They have established commercial infrastructure, deep relationships with healthcare providers, and the resources to invest in large-scale clinical programs and market access strategies. They are also better equipped to manage the product life cycle by expanding indications, generating real-world evidence, and sustaining relevance over time.
The impact of these capabilities is stark. Large companies account for a disproportionate share of late entrants that outperform the first product in class. By contrast, smaller companies rarely achieve the same outcome, particularly when entering later without strong differentiation.
This is not simply a question of budget. It reflects the complexity of competing in mature therapeutic markets, where success requires coordinated execution across clinical development, regulatory strategy, pricing, access and commercialisation.
For smaller biopharma players, this creates a strategic inflection point. Pursuing a late-entry strategy independently carries significant risk. In many cases, partnerships or licensing agreements with larger organisations provide a more viable path to unlocking value.
A more selective model for late entry biopharma strategy
Taken together, these dynamics point to a more disciplined approach to late-market strategy.
Late entry is no longer a default extension of pipeline logic. It is a high-bar strategic choice that requires alignment across three dimensions:
- Speed: Can the product reach the market within the early adoption window?
- Differentiation: Does it offer clear, clinically meaningful value?
- Scale: Does the organisation have the capabilities to execute effectively?
These dynamics reflect a wider strategic recalibration underway across the sector, as explored in this analysis of biopharma priorities for 2026.
When these elements align, late entrants can still achieve strong commercial performance, and in some cases, surpass first movers. When they do not, the likelihood of success drops sharply.
This has important implications for portfolio decision-making. For assets more than two years overdue and lacking meaningful differentiation, companies should reassess further investment. Redirecting development toward more targeted patient segments, pursuing alternative indications, or exploring partnerships may yield a more attractive return.
Conversely, where differentiation is strong (particularly in efficacy or safety), it may never be “too late.” Even in established markets, compelling clinical data can drive switching and reshape treatment standards.
What this means for executives
For leadership teams evaluating late-entry opportunities, the strategic priorities are straightforward:
- Move early or don’t move at all: The first two years define the competitive landscape.
- Prioritise meaningful differentiation: Focus development on outcomes that change clinical practice, not just improve metrics.
- Invest for scale or partner for it: Commercial success requires more than a good product.
- Be selective: Not every follower asset justifies full development and launch investment.
As a principle, a well-executed late entry biopharma strategy is not a fallback, it is a deliberate, high-bar commitment. Late entry in biopharma is not inherently disadvantaged, but it is unforgiving. The window of opportunity closes faster than many expect. Without speed, differentiation and scale, most late entrants will struggle to gain relevance, regardless of their scientific merit.
But when these factors come together, the outcome can be transformative. Late entrants can redefine standards of care, capture significant market share, and deliver substantial commercial value.
The question is no longer whether it is possible to succeed as a follower. It is whether companies are prepared to meet the much higher bar required to do so.
Author Bio
Christian Seiffert, Biopharma and Life Sciences Partner at L.E.K. Consulting
Christian Seiffert is a partner in L.E.K. Consulting‘s European Life Sciences practice. He joined L.E.K. as a partner in 2016 and focuses on developing strategies for commercialization, go-to-market and product launch as well as corporate strategy. Christian has extensive consulting experience, and he has provided strategic recommendations to leading pharmaceutical, biotechnology and medical technology organizations for more than 20 years.
Disclaimer: This article reflects the author’s analysis and is provided for informational purposes only; it does not constitute medical, legal, or official editorial advice from Life Science Daily News. The author is a Partner at L.E.K. Consulting, a global strategy consultancy.
